1056639-11-2

Basic information

• Product Name: 1-benzyl-1H-pyrazole-4-carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide
• Synonyms: 1-benzyl-1H-pyrazole-4-carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide
• CAS NO: 1056639-11-2
• Molecular Weight: 368.395
• Mol File: 1056639-11-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-benzyl-1H-pyrazole-4-carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzyl-1H-pyrazole-4-carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide(1056639-11-2)
• EPA Substance Registry System: 1-benzyl-1H-pyrazole-4-carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide(1056639-11-2)

Safety Data

• Hazardous Substances Data: 1056639-11-2(Hazardous Substances Data)

Upstream product

• 401647-24-3 1-benzyl-1H-pyrazole-4-carboxylic acid 
• 142665-13-2 5,6-diamino-3-propyluracil 

Downstream Products

• 1310114-75-0 8-(1-benzyl-1H-pyrazol-4-yl)-2-chloro-1-propyl-1,7-dihydro-purin-6-one 
• 1188541-73-2 3-{3-[4-(2,6-dioxo-1-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)pyrazol-1-yl]prop-1-ynyl}benzoic acid 
• 1188541-72-1 1-propyl-8-{1-[3-(4-trifluoromethoxyphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-67-4 1-propyl-8-{1-[3-(3-trifluoromethoxyphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-70-9 1-propyl-8-{1-[3-(4-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-66-3 1-propyl-8-{1-[3-(3-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2, 6-dione 
• 1188541-68-5 8-{1-[3-(4-fluorophenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-3,7-dihydropurine-2,6-dione 
• 1188541-69-6 8-{1-[3-(3-fluorophenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-3,7-dihydropurine-2,6-dione 
• 1243706-66-2 8-{1-[3-(4-fluoro-phenyl)-prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-2-pyrrolidin-1-yl-1,7-dihydro-purin-6-one 
• 1243707-98-3 8-{1-[3-(4-fluoro-phenyl)-prop-2-ynyl]-1H-pyrazol-4-yl}-1-propyl-2-pyrrolidin-1-yl-7-(2-trimethylsilanyl-ethoxymethyl)-1,7-dihydro-purin-6-one 
• 1243707-95-0 8-(1-benzyl-1H-pyrazol-4-yl)-1-propyl-2-pyrrolidin-1-yl-7-(2-trimethylsilanyl-ethoxymethyl)-1,7-dihydro-purin-6-one 
• 1243707-93-8 8-(1-benzyl-1H-pyrazol-4-yl)-1-propyl-2-pyrrolidin-1-yl-1,7-dihydro-purin-6-one 
• 1243707-73-4 8-(1-benzyl-1H-pyrazol-4-yl)-2-chloro-1-propyl-7-(2-trimethylsilanyl-ethoxymethyl)-1,7-dihydro-purin-6-one 
• 1243706-90-2 8-(1-benzyl-1H-pyrazol-4-yl)-1-propyl-2-(4-trifluoromethyl-benzylamino)-1,7-dihydro-purin-6-one 

Relevant articles and documents

Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases

Adenosine induces bronchial hyperresponsiveness and inflammation in asthmatics through activation of A2B adenosine receptor (A2BAdoR). Selective antagonists have been shown to attenuate airway reactivity and improve inflammatory cond

SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS

The present invention discloses substituted fused pyrimidine compounds of formula I, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides provide the use of compounds of formula (II), or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts thereof, for the treatment of a pathological disease susceptible to improvement by antagonism of adenosine receptors. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.